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Zusammenfassung
Hintergrund: Das Carbohydrat-Antigen 19-9 (CA 19-9) ist
gegenwärtig der beim Pankreaskarzinom am häufigsten
eingesetzte Tumormarker. Bei Patienten mit metastasier-
tem Pankreaskarzinom können sowohl anhand der prä-
therapeutischen CA-19-9-Spiegel als auch anhand der
CA-19-9-Kinetik unter Chemotherapie prognostische
Aussagen bezüglich des Überlebens getroffen werden.
Fallberichte: Wir berichten über zwei Patienten mit meta-
stasiertem Pankreaskarzinom, die im Rahmen einer palli-
ativen Chemotherapie mit Gemcitabin behandelt wur-
den. Beide Patienten zeigten bei Therapiebeginn hoch-
signifikant erhöhte CA-19-9 Werte (7505 und 150 000
U/ml), unter Chemotherapie mit Gemcitabin kam es je-
doch bei beiden Patienten zu einem deutlichen Abfall
(>90%) in der CA-19-9-Kinetik. Bei beiden Patienten konn-
te eine gute Krankheitskontrolle sowie ein klinischer Be-
nefit erreicht werden. Die Zeit bis zum Fortschreiten der
Erkrankung betrug 30 bzw. 28 Wochen, das Gesamtüber-
leben lag bei 14 bzw. 11 Monaten. Schlussfolgerung:
Diese Daten zeigen, dass die CA-19-9-Kinetik unter Che-
motherapie möglicherweise als nützlicher Surrogatmar-
ker für die Zeit bis zur Tumorprogression bzw. für das
Überleben beim fortgeschrittenen Pankreaskarzinom
fungieren kann.
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Summary
Background: The carbohydrate antigen 19-9 (CA 19-9) is
currently the most widely used serum tumor marker in
pancreatic cancer (PC). CA 19-9 pretreatment levels as
well as CA 19-9 kinetics during systemic chemotherapy
can provide prognostic information regarding survival of
patients with metastatic PC. Case Reports: We report the
clinical course of 2 patients with metastatic PC who un-
derwent palliative chemotherapy with gemcitabine. Both
patients showed a significant elevation of pretreatment
CA 19-9 levels (7,505 and 150,000 U/ml, respectively),
however, subsequently they experienced a highly signifi-
cant reduction (>90%) of CA 19-9 kinetics under gemci-
tabine chemotherapy. A good disease control and a clin-
ical benefit response were achieved in both patients.
Time to tumor progression was 30 weeks and 28 weeks,
overall survival 14 months and 11 months, respectively.
Conclusion: These data indicate that CA 19-9 kinetics
under chemotherapy may possibly serve as a useful sur-
rogate marker for time to tumor progression and survival
in advanced PC.
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Introduction
Pancreatic cancer (PC) is the 4th most frequent cause of death
from cancer in Germany, and the estimated annual incidence
is about 12/100,000. Over the last decade, the incidence of PC
in men was constant, whereas in women it increased over the
last years [1]. Survival still remains poor with a 5-year survival
rate of only 4% in all patients. In patients with an advanced
stage of disease, single-agent gemcitabine (Gem) is regarded
as the standard of care for the first-line chemotherapeutic
treatment, based on its improvement in clinical benefit re-
sponse and survival [2]. Known prognostic factors for survival
in patients with advanced PC are stage of disease, degree of
tumor cell differentiation, weight loss, performance status, and
primary tumor site [3, 4]. Furthermore, also the serum tumor
marker carbohydrate antigen 19-9 (CA 19-9) can provide
prognostic information. CA 19-9 is a tumor-associated antigen
(first described by Koprowski et al.) defined by a monoclonal
antibody (1116 NS 19-9) which was produced by a hybridoma
prepared from mouse spleen, immunized with a human col-
orectal carcinoma cell line [5, 6]. CA 19-9 is the sialylated
Lewis (Le)a blood group antigen, and individuals with a Lea–b–
phenotype (lacking the Lewis antigen glycosyltransferase) are
unable to synthesize CA 19-9 [7]. In patients receiving sys-
temic chemotherapy for advanced PC, pretreatment CA 19-9
levels were found to be a significant and also independent ad-
verse prognostic factor for survival [8–10]. However, also a
CA 19-9 decline (‘CA 19-9 response’) under chemotherapy
may serve as predictor of survival [8, 11–17]. Nevertheless,
there is no unique cut-off point defined for classifying a pa-
tient as a ‘CA 19-9 responder’ up to now. In order to separate
patients with advanced PC into the two groups of ‘CA 19-9 re-
sponder’ and ‘CA 19-9 nonresponder’, most studies used a de-
cline of pretreatment CA 19-9 levels of >20% or >50% after 8
weeks of treatment, respectively (table 1).
In this paper, we report the clinical course of two patients with
metastatic PC who showed highly elevated CA 19-9 pretreat-
ment values, but subsequently developed a strong CA 19-9 re-
sponse under systemic chemotherapy with Gem. Based on
these two cases, we furthermore discuss the question what
clinical information CA 19-9 values can provide to assess
prognosis in patients with advanced PC.
Case Report
Case 1
A 46-year-old female with painless icterus was admitted to our hospital in
August 2004. She had no particular past or family history. Physical exami-
nation revealed icteric conjunctiva, and laboratory studies found a total
bilirubin level of 5.3 mg/dl at presentation. Imaging studies (abdominal ul-
trasound and CT scan) showed an extrahepatic cholestasis caused by a
mass in the head of the pancreas with multiple synchronous liver metas-
tases. After placement of a bile duct stent by endoscopic retrograde
cholangiopancreatography (ERCP), a CT-guided biopsy of a liver lesion
histologically revealed a poorly differentiated (G3) adenocarcinoma. At
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the beginning of a systemic chemotherapy with single-agent Gem, CA 19-
9 values were found to be elevated with a pretreatment level of 7,505
U/ml (Elecsys®, Roche Diagnostics, Mannheim). The reference range was
defined as levels <37.0 U/ml. At that time, the serum bilirubin level was
within the reference range (1.1 mg/dl), and there were – also on imaging –
no signs of cholestasis. CA 19-9 kinetics under chemotherapy of this pa-
tient are shown in figure 1A. After 8 weeks of Gem treatment, a CA 19-9
reduction of about 91% (672 U/ml) was observed. The CA 19-9 nadir was
reached 15 weeks after treatment initiation with a level of 112 U/ml. Dur-
ing therapy the patient was doing well, no pain medication was required,
body weight was stable, and Karnofsky performance status (KPS) was
90%. The bile duct stent was routinely replaced every 3 months with no
further laboratory or imaging signs of extrahepatic cholestasis. According
to the Response Evaluation Criteria in Solid Tumors (RECIST) the best
response on imaging was stable disease, with no change in the diameter of
the primary tumor in the pancreas and a nearly complete disappearance
Table 1. Impact of CA 19-9 reduction in response to chemotherapy with
gemcitabine on survival in patients with advanced PC
Author CA 19-9 Median overall survival, 
reduction, months
%
Responder Nonresponder
Halm et al., 2000 [13] >20 8.9 3.7 (p < 0.001)
Saad et al., 2002 [8] >50 13.8 8.0 (p = 0.0272)
Ziske et al., 2003 [15] >20 12.8 8.1 (p = 0.006)
Ko et al., 2005 [17] >25 9.61 4.64 (p < 0.001)
>50 10.8 5.82 (p < 0.001)
>75 12.0 6.0 (p < 0.001)
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Fig. 1. Kinetics of CA 19-9 during chemotherapy with gemcitabine in 
patient 1 (A) and patient 2 (B).
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of all hepatic lesions (fig. 2). After 19 weeks a first rise in CA 19-9 levels
was detected; a CT scan performed 30 weeks after the start of Gem con-
firmed hepatic tumor progression. The patient received further chemo-
therapy with capecitabine, Gem plus oxaliplatin (GemOx) and peme-
trexed, but with none of these agents further disease stabilization could be
achieved. The patient died due to disease progression in October 2005
(resulting in an overall survival of 14 months from initial diagnosis). 
Case 2
A 73-year-old female was admitted to our department in July 2005 due to
a consecutive weight loss and epigastric and back pain. There were no
pathological findings in physical examination, the values of routine labora-
tory sampling (blood count, liver and renal function, coagulation) were
within the normal range. An abdominal CT scan showed a tumor in the
head of the pancreas with multiple hypodense liver lesions. Histology after
CT-guided biopsy of a liver mass yielded the diagnosis of an intermediately
to poorly differentiated ductal adenocarcinoma (G2-3). The patient was
randomized to first-line chemotherapeutic treatment with oral capecitabine
within a multicenter phase III trial. After two cycles of chemotherapy, an in-
tensive increase of CA 19-9 values was detected (pretreatment CA 19-9
level: 27,177 U/ml; after two cycles of capecitabine: 150,000 U/ml) without
any laboratory or imaging signs of cholestasis. A staging CT scan confirmed
progression of hepatic metastases, and subsequently the therapy was
switched (according to the study protocol) to single-agent Gem. CA 19-9 ki-
netics under second-line chemotherapy with Gem are summarized in figure
1B. After 8 weeks of chemotherapy, a strong CA 19-9 reduction of nearly
99% (2,092 U/ml) was observed. The CA 19-9 nadir was reached 14 weeks
after treatment initiation with Gem with a level of 1,261 U/ml. Clinically the
patient was doing well, an increase of KPS from 80% to 90% was observed.
Best response on imaging – according to RECIST – was a partial remission
documented in a CT scan 18 weeks after start of Gem. A hepatic tumor
progression was detected in the CT scan performed 28 weeks after the start
of single-agent Gem. The chemotherapy regimen was therefore again
changed to oxaliplatin in combination with leucovorin-modulated 5-fluo-
rouracil (as continuous infusion) in March 2006. After only one cycle of this
salvage regimen, the patient again showed a disease progression and devel-
oped a malignant stenosis of the bile duct, which could not be controlled by
ERCP-guided stenting or percutaneous drainage. The patient died due to a
sepsis with Enterococcus faecium in May 2006 (11 months after first diagno-
sis of metastatic PC).
Discussion
CA 19-9 is currently the most widely used serum tumor mark-
er in PC. For patients with advanced stages of disease there is
evidence that not only the pretreatment levels of CA 19-9 can
serve as prognostic factor, but also kinetics under chemother-
apy can provide useful prognostic information regarding sur-
vival. Published data for the prognostic impact of CA 19-9 ki-
netics (‘CA 19-9 response’) in trials using single-agent Gem
as palliative first-line treatment are summarized in table 1.
Nevertheless there is, to date, no clinical trial that addressed
the specific question which parameter would be the more use-
ful one for identifying patients with a favorable prognosis:
pretreatment CA 19-9 levels or CA 19-9 kinetics during
chemotherapy. 
Both patients reported in this paper had a highly elevated CA
19-9 level at treatment initiation with Gem. According to data
published by Maisey et al. [9] and Saad et al. [8] the median
overall survival in patients with pretreatment CA 19-9 levels
>1,000 U/ml ranges between 5.5 and 7.4 months. However, as
described above, our two patients experienced a strong and
long-lasting CA 19-9 reduction under chemotherapy with sin-
gle-agent Gem. This CA 19-9 decline correlated well with a
significant prolongation of the time to tumor progression (de-
fined by imaging criteria according to RECIST) of 30 weeks
and 28 weeks, respectively. According to all published phase
III trials that evaluated the role of chemotherapy in advanced
PC, the median time to tumor progression with single-agent
Gem ranges between only about 10 to 16 weeks [18, 19]. Our
data also are comparable with the findings of Ko et al. [17]
showing that a reduction of pretreatment CA 19-9 levels of
more than 75% under a fixed dose rate Gem therapy is a
strong prognostic factor yielding a prolonged median survival
of about 12 months (table 1).
Based on our clinical observations reported in this paper, we
would hypothesize that CA 19-9 kinetics under Gem chemo-
therapy may possibly serve as an even more useful prognostic
parameter than the absolute pretreatment values of CA 19-9.
Therefore we recommend, like other groups as well [9], fur-
ther investigation of this issue in the setting of controlled clin-
ical trials. Only if unique and standardized CA 19-9 measure-
ments will be included in large randomized phase III trials, the
value of their prognostic significance – regarding both pre-
treatment values and kinetics under chemotherapy – can be
defined. 
Fig. 2. Radiographic response to gemcitabine
in an abdominal CT scan after 19 weeks of
chemotherapy (patient 1): nearly complete
disappearance of all hepatic lesions.
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